Lexicon Pharmaceuticals (LXRX) Posts Narrower than Expected Q2 Loss of 5c/Sh.
Get Alerts LXRX Hot Sheet
Price: $1.54 -3.75%
Financial Fact:
Interest expense: -1.65M
Today's EPS Names:
FRSB, DGICA, UXIN, More
Financial Fact:
Interest expense: -1.65M
Today's EPS Names:
FRSB, DGICA, UXIN, More
Join SI Premium – FREE
Lexicon Pharmaceuticals (NASDAQ: LXRX) reported Q2 EPS of ($0.05), $0.01 better than the analyst estimate of ($0.06). Revenue for the quarter came in at $555 thousand versus the consensus estimate of $350 thousand.
For earnings history and earnings-related data on Lexicon Pharmaceuticals (LXRX) click here.
For earnings history and earnings-related data on Lexicon Pharmaceuticals (LXRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Intel (INTC) tops Q1 EPS by 3c; misses on guidance
- Cincinnati Financial (CINF) Tops Q1 EPS by 8c
- Roku (ROKU) Tops Q1 EPS by 26c, Revenue Beats, Offers Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!